Abatacept may reduce graft-versus-host disease after hematopoietic stem cell transplantation – Healio
|
Abatacept may reduce graft-versus-host disease after hematopoietic stem cell transplantation
Healio The addition of abatacept to standard therapy reduced the incidence of severe acute graft-versus-host disease to less than 5%, according to phase 2 study results presented at ASH Annual Meeting and Exposition. Incidence of grade 3 or grade 4 GVHD … |
